Loading...
Market
First Major Market to Approve GSK COVID-19 Vaccine by End of 2024
2
Resolution / Starting Odds
USA • 25%
EU • 25%
UK • 25%
Other • 25%
Official announcements from regulatory agencies
Story
GSK Secures Full Rights to Develop COVID-19 and Influenza Vaccines from CureVac
Jul 3, 2024, 06:30 AM
GlaxoSmithKline (GSK) has announced a new licensing agreement with CureVac, securing full rights to develop and manufacture COVID-19 and influenza vaccines. This strategic investment in vaccine platform technologies aims to enhance GSK's ability to match the best platform to each pathogen, ultimately helping to prevent illness in more people worldwide.
View original story
Similar markets
United States • 25%
European Union • 25%
China • 25%
Other • 25%
USA • 25%
Finland • 25%
Japan • 25%
Other EU country • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
None of the above • 25%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Other • 25%
European Union • 25%
Canada • 25%
Japan • 25%
Australia • 25%